Aliases & Classifications for Urticaria

About this section

Aliases & Descriptions for Urticaria:

Name: Urticaria 10 47 12 65

Classifications:



External Ids:

Disease Ontology10 DOID:1555
ICD9CM29 708.8
ICD1027 L50
UMLS65 C0029839, C0042109

Summaries for Urticaria

About this section
Disease Ontology:10 A skin disease characterized by skin rash notable for pale red, raised and itchy bumps, located in the upper dermis.

MalaCards based summary: Urticaria is related to cryopyrin-associated periodic syndrome and adenocarcinoma. An important gene associated with Urticaria is NLRP3 (NLR Family, Pyrin Domain Containing 3), and among its related pathways are Platelet Aggregation Inhibitor Pathway, Pharmacodynamics and IgA-Producing B Cells in the Intestine. The drugs diphenhydramine hydrochloride and diphenhydramine have been mentioned in the context of this disorder. Affiliated tissues include the upper dermis, skin and testes, and related mouse phenotypes are digestive/alimentary and integument.

Wikipedia:68 Urticaria (from the Latin urtica, \"nettle\" from urere, \"to burn\"), commonly referred to as hives, is... more...

Related Diseases for Urticaria

About this section

Diseases related to Urticaria via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 1015)
idRelated DiseaseScoreTop Affiliating Genes
1cryopyrin-associated periodic syndrome30.8CD40LG, CD79A
2adenocarcinoma30.5CD40LG, CD79A, F2
3purpura30.3CD40LG, CD79A
4typhus30.1CD40LG, CD79A
5erdheim-chester disease30.1CD40LG, TNF
6vulvovaginitis30.0CD79A, F2, NLRP3
7hydronephrosis29.9F2, IL10, TNF
8nasopharyngitis29.8CCL11, CXCL8, IL13
9fatty liver disease29.8CD40LG, F2, TNF
10alpha chain disease29.7CD40LG, CD79A
11villonodular synovitis29.6CD40LG, CD79A, CXCL8
12meige syndrome29.6CD40LG, IL10, TNF
13mycobacterium abscessus29.6CXCL8, IL10, TPT1
14lateral sclerosis29.5CD40LG, F2, IL10, TNF
15narcissistic personality disorder29.5CD40LG, CD79A, CPN1, CXCL8
16cryoglobulinemia29.5CD40LG, CD79A, IL1RN, TNF
17primary ciliary dyskinesia29.5CD40LG, CD79A, F2, TNF
18bronchopulmonary dysplasia29.3CXCL8, IL10, IL13, TNF
19severe acute respiratory syndrome29.3CCL11, CXCL8, IL10, IL13, TNF
20capillary hemangioma29.3CCL11, CD40LG, CD79A, CMA1, HRH1, IL13
21alcoholic liver cirrhosis29.2CXCL8, F2, IL10, TNF
22cryptococcosis29.1CCL11, HRH1, IL10, IL13, IL3, TPT1
23systemic lupus erythematosus29.0C1S, CD40LG, CD79A, IL10, TNF
24acalculous cholecystitis28.8CCL11, CD79A, CXCL8, HRH1, IL10, IL13
25rheumatoid arthritis28.7CD40LG, CD79A, CXCL8, IL10, IL1RN, NLRP3
26malaria28.1CCL11, CD40LG, CXCL8, HRH1, IL10, IL13
27asthma27.1CCL11, CD40LG, CD79A, CXCL8, FCER1A, HRH1
28arthus reaction26.7C1S, CCL11, CD40LG, CD79A, CMA1, CPN1
29vibratory urticaria12.6
30cold urticaria12.6
31cholinergic urticaria12.6
32solar urticaria12.5
33urticaria pigmentosa12.5
34allergic urticaria12.4
35aquagenic urticaria12.4
36physical urticaria12.4
37papular urticaria12.3
38plaque-form urticaria pigmentosa12.2
39typical urticaria pigmentosa12.2
40nodular urticaria pigmentosa12.2
41schnitzler syndrome12.1
42familial cold autoinflammatory syndrome 312.0
43muckle-wells syndrome12.0
44dermatographia11.8
45familial cold-induced inflammatory syndrome 111.8
46maculopapular cutaneous mastocytosis11.8
47angioedema11.8
48familial cold autoinflammatory syndrome11.5
49familial dermographism11.4
50erythema multiforme10.7

Graphical network of the top 20 diseases related to Urticaria:



Diseases related to urticaria

Symptoms for Urticaria

About this section

Drugs & Therapeutics for Urticaria

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)15 Company Approval Date
1
Clarinex15 DESLORATADINE Schering-Plough February 2002
FDA Label: Clarinex
Disease/s that Drug Treats:Allergic rhinitis; Chronic ideopathic urticaria
Indications and Usage:15 CLARINEX is an H1-receptor antagonist indicated for: * Seasonal Allergic Rhinitis: relief of nasal and non-nasal symptoms in patients 2 years of age and older. (1.1) * Perennial Allergic Rhinitis: relief of nasal and non-nasal symptoms in patients 6 months of age and older. (1.2) * Chronic Idiopathic Urticaria: symptomatic relief of pruritus, reduction in the number of hives, and size of hives in patients 6 months of age and older. (1.3)
DrugBank Targets:13 Histamine H1 receptor
Mechanism of Action:15 
Target: histamine
Action: long-acting tricyclic antagonist
FDA: Desloratadine is a long-acting tricyclic histamine antagonist with selective H1-receptor histamine antagonist activity. Receptor binding data indicates that at a concentration of 2-3 ng/mL (7 nanomolar), desloratadine shows significant interaction with the human histamine H1-receptor. Desloratadine inhibited histamine release from human mast cells in vitro. Results of a radiolabeled tissue distribution study in rats and a radioligand H1-receptor binding study in guinea pigs showed that desloratadine did not readily cross the blood brain barrier. The clinical significance of this finding is unknown.

Drugs for Urticaria (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 248)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Omalizumabapproved, investigationalPhase 4, Phase 2, Phase 3, Phase 1137242138-07-4
Synonyms:
242138-07-4
D05251
Ig gamma-1 chain C region
Omalizumab
 
Omalizumab (USAN/INN)
Omalizumab (genetical recombination)
Omalizumab (genetical recombination) (JAN)
Xolair
Xolair (TN)
2
FexofenadineapprovedPhase 4, Phase 25883799-24-03348
Synonyms:
159389-12-5
2-[4-(1-hydroxy-4-{4-[hydroxy(diphenyl)methyl]piperidin-1-yl}butyl)phenyl]-2-methylpropanoic acid
2-[4-[1-hydroxy-4-[4-[hydroxy(diphenyl)methyl]piperidin-1-yl]butyl]phenyl]-2-methylpropanoic acid
4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)-1-piperidinyl)butyl)-alpha,alpha-dimethylbenzeneacetic acid
76815-58-2
83799-24-0
AC1L1FQB
Allegra
Allegra-D 12 Hour
Allegra-D 24 Hour
BRD-A73368467-003-02-8
BSPBio_003521
C06999
C32H39NO4
CHEBI:5050
CHEMBL914
CID3348
Carboxyterfenadine
D07958
DB00950
EU-0100488
F 9427
Fexofenadine
Fexofenadine (INN)
Fexofenadine Hydrochloride
Fexofenadine [INN:BAN]
Fexofenadine hydrochloride
Fexofendine
Fexofenodine Hydrochloride
HSDB 7486
 
KBio2_002449
KBio2_005017
KBio2_007585
KBio3_002742
KBioGR_000807
KBioSS_002456
L000869
LS-28827
Lopac0_000488
MDL 16455
MolPort-002-508-207
NCGC00015453-03
NCGC00015453-06
NCGC00092389-02
NCGC00092389-03
SPBio_001197
STK624102
STOCK6S-26154
Spectrum2_001179
Spectrum3_001921
Spectrum4_000204
Spectrum5_001474
Spectrum_001914
Telfast
Telfast (TN)
Terfenadine acid metabolite
Terfenadine carboxylate
Terfenadine-COOH
Terfenidine carboxylate, MDL 16455
UNII-E6582LOH6V
fexofenadine
3
Desloratadineapproved, investigationalPhase 4, Phase 3, Phase 269100643-71-8124087
Synonyms:
100643-71-8
8-Chloro-11-piperidin-4-ylidene-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine
8-Chloro-6,11-dihydro-11-(4-piperidinylidene)-5H-benzo(5,6)cyclohepta(1,2-b)pyridine
8-chloro-11-(piperidin-4-ylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine
8-chloro-6,11-dihydro-11-(4-Piperidinylidene)-5H-benzo(5,6)cyclohepta(1,2-b)pyridine
AC-1279
AC1L3XUD
AKOS000280921
Aerius
Allex
Azomyr
BB_SC-2104
C121345
CHEBI:291342
CHEMBL1172
CID124087
CPD000149358
Claramax
Clarinex
Clarinex (TN)
Clarinex RediTabs
Clarinex Reditabs
D03693
D3787
DB00967
DESLORATADINE
Denosin
Desalex
Descarboethoxyloratadine
Descarboethoxyoratidine
 
Desloratadine
Desloratadine (USAN/INN)
Desloratadine [USAN]
Desloratidine
Essex brand of desloratadine
HMS2052H05
HMS2090C06
HMS2093F19
I06-1866
L001025
LS-181814
MLS000559042
MLS000759406
MLS001201801
MolPort-000-883-875
NCGC00159325-02
NCGC00159325-03
NCGC00159325-04
NSC675447
NeoClarityn
Neoclarityn
Opulis
SAM001246545
SMR000149358
STK586537
Sch 34117
Sch-34117
Schering brand of desloratadine
Schering-Plough brand of desloratadine
TL8000065
UNII-FVF865388R
desloratadine
4
CefazolinapprovedPhase 410125953-19-9656510, 33255
Synonyms:
(6R, 7R)-3-[[(5-Methyl-1,3,4-thiadiazol-2- yl)thio]methyl]-8-oxo-7-[[1H-tetrazol-1- yl)acetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2- ene-2-carboxylic acid
(6R,7R)-3-(((5-Methyl-1,3,4-thiadiazol-2-yl)thio)methyl)-8-oxo-7-(2-(1H-tetrazol-1-yl)acetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid
(6R,7R)-3-[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanylmethyl]-8-oxo-7-[[2-(tetrazol-1-yl)acetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6R,7R)-3-{[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl}-8-oxo-7-[(1H-tetrazol-1-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6R,7R)-3-{[(5-methyl-1,3,4-thiadiazol-2-yl)thio]methyl}-8-oxo-7-[(1H-tetrazol-1-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6R-trans)-3-(((5-Methyl-1,3,4-thiadiazol-2-yl)thio)methyl)-8-oxo-7-(((1H-tetrazol-1-yl)acetyl)-amino)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid
25953-19-9
27164-46-1
3-{[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl}-7beta-[(1H-tetrazol-1-ylacetyl)amino]-3,4-didehydrocepham-4-carboxylic acid
7-(1-(1H-)-Tetrazolylacetamido)-3-(2-(5-methyl-1,3,4-thiadiazolyl)thiomethyl)delta3-cephem-4-carboxylic acid
AC-16010
AC1L1P98
AC1Q6LOT
BPBio1_000762
BRN 4169371
BSPBio_000692
BSPBio_001939
Bio-0576
C06880
C14H14N8O4S3
CEZ
CHEBI:474053
CHEMBL1435
CID33255
Cefamezin
Cefamezine
Cefazolin
Cefazolin (USP)
Cefazolin Sodium
Cefazolin [USAN:INN]
Cefazolin sodium
Cefazolina
Cefazolina [INN-Spanish]
Cefazoline
Cefazoline [INN-French]
Cefazolinum
Cefazolinum [INN-Latin]
Cephamezine
 
Cephazolidin
Cephazolin
Cephazolin Sodium
Cephazoline
D02299
DivK1c_000014
EINECS 247-362-8
Elzogram
HSDB 3213
IDI1_000014
KBio1_000014
KBio2_000546
KBio2_003114
KBio2_005682
KBio3_001159
KBioGR_000734
KBioSS_000546
LS-150084
Lopac0_000274
MLS001032060
MLS001049010
MolPort-002-507-461
NCGC00159465-02
NINDS_000014
NSC291561
Prestwick0_000736
Prestwick1_000736
Prestwick2_000736
Prestwick3_000736
SMR000387025
SPBio_001039
SPBio_002631
Spectrum2_001140
Spectrum3_000330
Spectrum4_000267
Spectrum5_000665
Spectrum_000106
UNII-IHS69L0Y4T
cefazolin
cefazolin(usp)
5
ClindamycinapprovedPhase 415718323-44-929029
Synonyms:
13441-63-9
16669-21-9
18323-44-9
21462-39-5 (mono-hydrochloride)
24620-78-8
24696-19-3
58207-19-5
7(S)-Chloro-7-deoxylincomycin
7-CDL
7-Chloro-7-deoxylincomycin
7-Chlorolincomycin
7-Deoxy-7(S)-chlorolincomycin
AC1L1EGQ
AC1L1GLA
AC1L9JV8
AC1MHD7N
AC1MHE1M
AC1MHUOE
AC1MHX4G
AC1NWAKO
AC1O7ENS
AC1O7GED
AC1OFCIP
AC1OFCIV
AC1OFCJ1
AC1OFCJ7
AC1OIBYJ
AC1OIBYL
AC1OIBYN
AC1Q2V4O
Antirobe
BIDD:GT0418
BPBio1_000236
BRD-A23034328-003-03-4
BSPBio_000214
BSPBio_002049
C06914
C18H33ClN2O5S
CAS-21462-39-5
CHEBI:3745
CHEMBL187
CID2786
CID29029
CID3000512
CID3001928
CID3032758
CID3034218
CID446598
CID5702026
CID6602476
CID6604361
CID7048642
CID7048644
CID7048646
CID7048648
CID7276014
CID7276016
CID7276018
CID9812677
CLDM
CLINDA & IL-12
CLY
Chlolincocin
Chlorlincocin
Chlorodeoxylincomycin
Chlorolincomycin
Cleocin
Cleocin (TN)
Cleocin (tn)
Cleocin HCl
Cleocin Hydrochloride
Cleocin T Gel
Cleocin T Lotion
Cleocin T Topical Solution
 
Clinda-derm
ClindaDerm
Clindagel
Clindamax
Clindamicina
Clindamicina [INN-Spanish]
Clindamycin
Clindamycin & Interleukin 12
Clindamycin & VRC3375
Clindamycin (USAN/INN)
Clindamycin Phosphate
Clindamycin [USAN:BAN:INN]
Clindamycine
Clindamycine [French]
Clindamycine [INN-French]
Clindamycinum
Clindamycinum [INN-Latin]
Clindesse
Clinimycin
D00277
DB01190
Dalacin C
Dalacin C Flavored Granules
Dalacin C Phosphate
Dalacin T Topical Solution
Dalacine
DivK1c_000464
EINECS 242-209-1
Evoclin
HMS2089A05
HMS2089N16
HSDB 3037
I06-0826
IDI1_000464
KBio1_000464
KBio2_000638
KBio2_003206
KBio2_005774
KBio3_001269
KBioGR_000844
KBioSS_000638
Klimicin
Klindan 300
LS-187128
LS-98131
MLS001183714
Methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-threo-alpha-D-galacto-octopyranoside
MolPort-002-323-206
MolPort-002-964-479
NCGC00016752-01
NCGC00178843-01
NCGC00179636-01
NINDS_000464
Prestwick0_000137
Prestwick1_000137
Prestwick2_000137
Prestwick3_000137
ResiDerm A
SMP2_000295
SMR000677917
SPBio_000670
SPBio_002153
STK177246
STOCK1N-31150
Sobelin
Spectrum2_000885
Spectrum3_000355
Spectrum4_000292
Spectrum5_001525
Spectrum_000158
U 21251
U-21,251
U-21251
UNII-3U02EL437C
Zindaclin
clindamycin
6
AzelastineapprovedPhase 4, Phase 33658581-89-82267
Synonyms:
37932-96-0 (unspecified hydrochloride)
4-((4-Chlorophenyl)methyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1(2H)-phthalazinone hydrochloride
4-((4-chlorophenyl)methyl)-2- (hexahydro-1-methyl-1H-azepin-4-yl)-1(2H)- phthalazinone HCl
4-(4-chlorobenzyl)-2-(1-methylazepan-4-yl)phthalazin-1(2H)-one
4-(P-Chlorobenzyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1-(2H)-phthalazinone
4-(p-Chlorobenzyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1-(2H)-phthalazinone
4-(p-chlorobenzyl)-2-(N-methylperhydroazepinyl-(4))-1-(2H)-phthalazinone
4-[(4-chlorophenyl)methyl]-2-(1-methylazepan-4-yl)phthalazin-1(2H)-one
4-[(4-chlorophenyl)methyl]-2-(1-methylazepan-4-yl)phthalazin-1-one
58581-89-8
79307-93-0 (hydrochloride)
AC1L1DAR
Astelin
Astepro
Azelastina
Azelastina [INN-Spanish]
Azelastine (INN)
Azelastine Hydrochloride
Azelastine [INN:BAN]
Azelastinum
Azelastinum [INN-Latin]
 
BRD-A68888262-003-02-9
BRN 0900747
BSPBio_003584
C07768
C22H24ClN3O
CHEBI:2950
CHEMBL639
CID2267
D07483
DB00972
I06-0157
I14-2736
KBio3_002992
L001153
LS-109214
NCGC00177979-01
Optivar
Optivar (TN)
SPBio_000657
Spectrum2_000649
Spectrum3_001984
UNII-ZQI909440X
azelastine
7
ClevidipineapprovedPhase 420166432-28-6
Synonyms:
 
Clevidipine butyrate
Cleviprex
8
PraziquantelapprovedPhase 43355268-74-14891
Synonyms:
(.+-)-2-(Cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino(2,1a)isoquinolin-4-one
(11bS)-2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one
135526-78-2
2-(Cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro- 4H-pyrazino[2,1-a]-isoquinolin-4-one
2-(Cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino(2,1-a)isoquinolin-4-one
2-(Cyclohexylcarbonyl)-1,2,3,6,7-11b-hexahydro-4H-pyrazino(2,1a)isoquinolin-4-one
2-(Cyclohexylcarbonyl)-1,2,3,6,7-11b-hexahydro-4H-pyrazinoe(2,1a)isoquinolin-4-one
2-(cyclohexanecarbonyl)-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one
2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one
2-Cyclohexanecarbonyl-1,2,3,6,7,11b-hexahydro-pyrazino[2,1-a]isoquinolin-4-one
2-Cyclohexylcarbonyl-1,2,3,6,7,11b-hexahydro-4H-pyrazino(2,1-a) isoquinolin-4-one
46648_FLUKA
46648_RIEDEL
5-24-03-00361 (Beilstein Handbook Reference)
55268-74-1
57452-31-0
8440, EMBAY
AB00052075
AC-11670
AC1L1J6N
AKOS000541869
Azinox
BAS 00347357
BPBio1_000088
BRD-A21858158-001-05-2
BRN 0761557
BSPBio_000080
BSPBio_002199
Bay-8440
Bayer Brand of Praziquantel
Biliricide
Biltricide
Biltricide (TN)
Biltricide, Droncit, Praziquantel
Bio-0456
C07367
CCRIS 4114
CHEMBL976
CID4891
CPD000037139
Cesol
Cisticid
Cutter
Cutter Tape Tabs
Cysticide
D00471
D011223
DB01058
DivK1c_000130
Droncit
Drontsit
EINECS 259-559-6
EINECS 260-741-2
EMBAY-8440
EU-0100909
Embay 8440
HMS1568D22
HMS1920J06
HMS2090J19
 
HMS2092A09
HMS500G12
I06-0088
IDI1_000130
InChI=1/C19H24N2O2/c22-18-13-20(19(23)15-7-2-1-3-8-15)12-17-16-9-5-4-6-14(16)10-11-21(17)18/h4-6,9,15,17H,1-3,7-8,10-13H
KBio1_000130
KBio2_001599
KBio2_004167
KBio2_006735
KBio3_001699
KBioGR_000963
KBioSS_001599
LS-23174
LS-7155
Lopac0_000909
MLS000028528
MLS000038419
MLS001201812
MLS001304085
Merck Brand of Praziquantel
MolPort-001-926-470
NCGC00015818-05
NCGC00015818-11
NCGC00089733-02
NCGC00089733-03
NCGC00089733-04
NCGC00089733-05
NINDS_000130
NPFAPI-02
Oprea1_163497
P 4668
P4668_SIGMA
Prasiquantel
Praziquantel (JAN/USP/INN)
Praziquantel [USAN:INN:BAN:JAN]
Praziquantel, (+-)-Isomer
Praziquantel, (R)-Isomer
Praziquantel, (S)-Isomer
Praziquantelum
Praziquantelum [INN-Latin]
Prestwick0_000260
Prestwick1_000260
Prestwick2_000260
Prestwick3_000260
Prestwick_402
Pyquiton
S1691_Selleck
SAM002264632
SMR000037139
SPBio_001295
SPBio_002299
SPECTRUM1500494
STK030186
Spectrum2_001288
Spectrum3_000550
Spectrum4_000482
Spectrum5_001064
Spectrum_001119
Traziquantel
UNII-6490C9U457
praziquantel
9
HydroxyzineapprovedPhase 41768-88-23658
Synonyms:
1-(p-Chloro-.alpha.-phenylbenzyl)-4-[2-[(2-hydroxyethoxy)ethyl]piperazine
1-(p-Chloro-alpha-phenylbenzyl)-4-(2-(2-hydroxyethoxy)ethyl)piperazine
1-(p-Chloro-alpha-phenylbenzyl)-4-(2-hydroxyethoxyethyl)piperazine
1-(p-Chlorobenzhydryl)-4-(2-(2-hydroxyethoxy)ethyl)diethylenediamine
1-(p-Chlorobenzhydryl)-4-(2-(2-hydroxyethoxy)ethyl)piperazine
1-(p-Chlorobenzhydryl)-4-[2-(2-hydroxyethoxy)ethyl]diethylenediamine
1-(p-Chlorobenzhydryl)-4-[2-(2-hydroxyethoxy)ethyl]piperazine
1-(p-Chlorodiphenylmethyl)-4-(2-(2-hydroxyethoxy)ethyl)piperazine
1-(p-Chlorodiphenylmethyl)-4-[2-(2-hydroxyethoxy)ethyl]piperazine
10246-75-0 (pamoate)
2-(2-(4-((4-Chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)ethanol
2-(2-(4-(p-Chloro-alpha-phenylbenzyl)-1-piperazinyl)ethoxy)ethanol
2-(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)ethanol
2-[(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethyl)oxy]ethanol
2-[2-[4-(p-Chloro-.alpha.-phenylbenzyl)-1-piperazinyl]ethoxy]ethanol
2-[2-[4-[(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]ethanol
2192-20-3 (di-hydrochloride)
5-23-01-00462 (Beilstein Handbook Reference)
68-88-2
AB00053485
AC1L1GFB
AKOS003334349
Atara
Atarax
Atarax base
Ataraxoid
Atarazoid
Atarox
Atazina
Aterax
BPBio1_000228
BRD-A62428732-096-02-6
BRD-A62428732-300-03-0
BRN 0321392
BSPBio_000206
C07045
C21H27ClN2O2
CHEBI:5818
CHEMBL896
CID3658
D08054
DB00557
Deinait
Durrax
EINECS 200-693-1
Ethanol, 2-(2-(4-((4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)- (9CI)
Fenarol
HSDB 3098
Hidroxizina
Hidroxizina [INN-Spanish]
Hy-Pam 25
Hychotine
Hydroksyzyny
Hydroksyzyny [Polish]
Hydroxine
 
Hydroxizine
Hydroxizinum
Hydroxycine
Hydroxyzin
Hydroxyzine
Hydroxyzine (INN)
Hydroxyzine Base
Hydroxyzine Hcl
Hydroxyzine Hydrochloride
Hydroxyzine Pamoate
Hydroxyzine [INN:BAN]
Hydroxyzine base
Hydroxyzine hydrochloride
Hydroxyzine pamoate
Hydroxyzinum
Hydroxyzinum [INN-Latin]
Hydroxyzyne
Idrossizina
Idrossizina [DCIT]
Idrossizina [Dcit]
L000930
LS-66601
Marex (TN)
MolPort-002-506-318
N-(4-Chlorobenzhydryl)-N'-(hydroxyethoxyethyl)piperazine
N-(4-Chlorobenzhydryl)-N'-(hydroxyethyloxyethyl)piperazine
NP 212
NSC 169188
NSC169188
Neurozina
Nevrolaks
Orgatrax
Pamazone
Parenteral
Paxistil
Placidol
Plaxidol
Prestwick0_000133
Prestwick1_000133
Prestwick2_000133
Prestwick3_000133
SPBio_002145
ST059726
Tran-Q
Tranquizine
Traquizine
U.C.B 4492
U.CB 4492
UCB 4492
UCB 492
UNII-30S50YM8OG
Vesparaz-Wirkstoff
Vistaril
WLN: T6N DNTJ AYR&R D6& D2O2Q
hydroxyzine
neo-Calma
10
IcatibantapprovedPhase 4, Phase 3, Phase 2, Phase 1, Phase 016138614-30-9, 130308-48-471364
Synonyms:
(2S)-2-[[(3aS,7aS)-1-[2-[(2S)-2-[[(2S)-2-[[2-[[(4R)-1-[1-[2-[[(2R)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]-3-thiophen-2-ylpropanoyl]amino]-3-hydroxypropanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid
(2s)-2-({[(3as,7as)-1-({2-[(2s)-2-{[(2s)-2-({[({(4r)-1-[(1-{2-({(2r)-2-amino-5-[(diaminomethylidene)amino]pentanoyl}amino)-5-[(diaminomethylidene)amino]pentanoyl}pyrrolidin-2-yl)carbonyl]-4-hydroxypyrrolidin-2-yl}carbonyl)amino]acetyl}amino)-3-(thiophen-2-yl)propanoyl]amino}-3-hydroxypropanoyl]-1,2,3,4-tetrahydroisoquinolin-3-yl}carbonyl)octahydro-1h-indol-2-yl]carbonyl}amino)-5-[(diaminomethylidene)amino]pentanoic acid(non-preferred name)
130308-48-4
138614-30-9 (acetate)
13996-86-6
153322-84-0
AC1L2G0Q
AC1Q5QRX
AR-1A3141
C59H89N19O13S
CHEBI:163731
CHEMBL411169
CID71364
 
D-Arg(Hyp(3)-Thi(5)-D-Tic(7)-Oic(8))BK
DB06196
Firazyr
HOE 140
HOE140
Hoe-140
Icatibant
Icatibant Acetate
Icatibant [INN]
JE049
KST-1A1301
LS-172762
WIN 65365
WIN-65365
11
CetirizineapprovedPhase 4, Phase 3, Phase 2, Phase 111783881-51-02678
Synonyms:
(2-(4-((4-Chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)acetic acid
(2-{4-[(4-Chloro-phenyl)-phenyl-methyl]-piperazin-1-yl}-ethoxy)-acetic acid
(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid
2-(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid
2-[2-[4-[(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]acetic acid
83881-51-0
83881-52-1 (di-hydrochloride)
AC-5545
AC1L1E7T
AC1Q768B
AKOS003589059
BPBio1_000469
BRD-A42571354-300-05-4
BSPBio_000425
BSPBio_002302
Benaday
C07778
C21H25ClN2O3
CHEBI:3561
CHEMBL1000
CID2678
CPD001453715
Cetiderm
Cetiderm (TN)
Cetirizin
Cetirizina
Cetirizina [Spanish]
Cetirizine
Cetirizine (INN)
Cetirizine Hydrochloride
Cetirizine Hydrochloride Hives Relief
Cetirizine [INN:BAN]
Cetirizine hydrochloride
Cetirizinum
Cetirizinum [Latin]
Cetrizine Hcl
Cetryn
 
D07662
DB00341
HMS1539O07
Hitrizin Film Tablet
Humex
I06-0454
Kirklands Childrens Aller Tec
L000655
LS-11409
Leader All Day Allergy
MLS002222268
MolPort-002-506-309
NCGC00167781-01
NCGC00167781-02
NCGC00167781-03
NCGC00167781-04
P-071
Prestwick0_000503
Prestwick1_000503
Prestwick2_000503
Prestwick3_000503
Reactine
SAM002589989
SMR000145214
SPBio_002346
STK711108
STOCK2S-03020
Setir
TimTec1_002075
UNII-YO7261ME24
Virlix
Ziptek
Zirtek
Zyrlex
Zyrtec
[(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethyl)oxy]acetic acid
cetirizine
nchembio714-comp3
12
Histamine PhosphateapprovedPhase 4, Phase 2, Phase 3, Phase 1, Phase 090651-74-165513
Synonyms:
1H-Imidazole-4-ethanamine, phosphate (1:2)
2-Imidazol-4-ylethylamine orthophosphoric acid (1:2)
4-(2-Aminoethyl)imidazole bis(dihydrogen phosphate)
4-(2-Aminoethyl)imidazole di-acid phosphate
4-2(2-Aminoethyl)Imidazole-Di-Acid Phosphate
51-74-1
53623-99-7
74-56-6
AC1L23E4
CID65513
D04445
DB00667
EINECS 200-118-4
 
H0147
Histamine Positive Skin Test Control
Histamine Positive skin test control
Histamine acid phosphate
Histamine biphosphate
Histamine dihydrogen phosphate
Histamine diphosphate
Histamine phosphate (1:2)
Histamine phosphate (TN)
Histamine phosphate (USP)
Histamine phosphate [USP]
Histamine positive
Histaminum
LS-78569
UNII-QWB37T4WZZ
13
Dapsoneapproved, investigationalPhase 46280-08-02955
Synonyms:
(4-sulfanilylphenyl)amine
1,1'-Sulfonylbis(4-aminobenzene)
1,1'-Sulfonylbis[4-aminobenzene]
1,1'-Sulphonylbis(4-aminobenzene)
1358F
32960_FLUKA
4,4' Diaminophenyl Sulfone
4,4'-Dapsone
4,4'-Diaminodiphenyl sulfone
4,4'-Diaminodiphenyl sulphone
4,4'-Diaminodiphenyl suphone
4,4'-Diaminodiphenylsulfone
4,4'-Sulfonylbisaniline
4,4'-Sulfonylbisbenzamine
4,4'-Sulfonylbisbenzenamine
4,4'-Sulfonylbisbenzeneamine
4,4'-Sulfonyldianilin
4,4'-Sulfonyldianiline
4,4'-Sulfonyldianiline (Dapsone)
4,4'-Sulphonylbisbenzamine
4,4'-Sulphonylbisbenzenamine
4,4'-Sulphonyldianiline
4,4'-diaminophenyl sulfone
4,4'-sulfonyldianiline
4,4-Diaminodifenylsulfon
4,4-Diaminodifenylsulfon [Czech]
4,4-Sulfonyldianiline
4-(4-Aminophenylsulfonyl)aniline
4-(4-Aminophenylsulfonyl)benzenamine
4-(4-amino-Benzenesulfonyl)-phenylamine
4-(4-aminophenyl)sulfonylaniline
4-Aminop henyl sulfone
4-Aminophenyl sulfone
4-Aminophenylsulfone
4-[(4-aminobenzene)sulfonyl]aniline
4-[(4-aminophenyl)sulfonyl]aniline
46158_FLUKA
46158_RIEDEL
80-08-0
A74807_ALDRICH
AB00051962
AB1004833
AC-10922
AC1L1EUH
AC1Q51WM
AC1Q51WN
AI3-08087
AKOS000119322
ALBB-005917
AZT + Dapsone cominbation
Acedapsone
Aczone
Aczone (TN)
Ambap80-08-0
Araldite HT
Araldite HT 976
Araldite Ht
Atrisone
Avlosulfon
Avlosulfone
Avlosulphone
Avsulfor
BIDD:GT0770
BPBio1_000143
BRD-K62363391-001-05-8
BRN 0788055
BSPBio_000129
BSPBio_002129
Bis(4-aminophenyl) sulfone
Bis(4-aminophenyl)sulfone
Bis(4-aminophenyl)sulphone
Bis(P-aminophenyl) sulfone
Bis(p-aminophenyl) sulfone
Bis(p-aminophenyl)sulphone
C07666
CAS-80-08-0
CBDivE_013582
CCRIS 192
CHEBI:4325
CHEMBL1043
CID2955
CPD000059064
Croysulfone
Croysulphone
D SS
D003622
D00592
D0089
DADPS
DAPSONE
DB00250
DDS
DDS (pharmaceutical)
DDS, diaphenylsulfone
DDS, pharmaceutical
DIAPHENYLSULFONE
DSS
DSS (VAN)
Dapsoderm-X
Dapson
Dapson-Fatol
Dapsona
Dapsona [INN-Spanish]
Dapsone
Dapsone (USP)
Dapsone [USAN:BAN]
Dapsonum
Dapsonum [INN-Latin]
Dds, Diaphenylsulfone
Dds, Pharmaceutical
Di(4-aminophenyl) sulfone
Di(4-aminophenyl)sulfone
Di(4-aminophenyl)sulphone
Di(p-aminophenyl) sulfone
Di(p-aminophenyl)sulphone
Diamino-4,4'-diphenyl sulfone
Diamino-4,4'-diphenyl sulphone
Diamino-diphenyl sulphone
Diaminodifenilsulfona
Diaminodifenilsulfona [Spanish]
Diaminodiphenyl Sulfone
Diaminodiphenyl sulfone
Diaminodiphenylsulfone
Diaphenylsulfon
 
Diaphenylsulfone
Diaphenylsulfone (JAN)
Diaphenylsulphon
Diaphenylsulphone
Dimitone
Diphenasone
Diphone
Disulone
DivK1c_000573
Dubronax
Dubronaz
Dumitone
EINECS 201-248-4
Eporal
F 1358
Fatol Brand of Dapsone
HMS1568G11
HMS1920C14
HMS2091K04
HMS501M15
HSDB 5073
HT 976
HY 976
Hardener HT 976
I01-3640
ICI
IDI1_000573
IN-201
KBio1_000573
KBio2_001368
KBio2_003936
KBio2_006504
KBio3_001349
KBioGR_000900
KBioSS_001368
LS-1790
MLS000069409
MLS001055349
MLS001076146
Metabolite C
Mex-America Brand of Dapsone
MolPort-001-780-172
N, N'-Diphenyl Sulfondiamide
N, N'-Diphenyl sulfondiamide
N,N'-Diphenyl sulfondiamide
NCGC00016322-01
NCGC00016322-02
NCGC00023946-03
NCGC00023946-04
NCGC00023946-05
NCGC00023946-06
NCI-C01718
NINDS_000573
NSC 6091
NSC 6091D
NSC-6091
NSC6091
Normet
Novophone
Oprea1_143052
Orsade Brand of Dapsone
P, P'-Sulfonyldianiline
P,P'-Diaminodiphenyl Sulfone
P,P'-diaminodiphenyl sulfone
P,P-Diaminodiphenyl Sulphone
P,P-Sulfonylbisbenzamine
P,P-Sulfonylbisbenzenamine
P,P-Sulphonylbisbenzamine
P,P-Sulphonylbisbenzenamine
P,P-Sulphonyldianiline
P-Aminophenyl Sulfone
P-Aminophenyl sulfone
Prestwick0_000035
Prestwick1_000035
Prestwick2_000035
Prestwick3_000035
Prestwick_152
Protogen
Recolip
SAM002554879
SMR000059064
SPBio_001025
SPBio_002050
SPECTRUM1500222
STK387118
Spectrum2_001133
Spectrum3_000375
Spectrum4_000310
Spectrum5_000825
Spectrum_000888
Sulfadione
Sulfanona-Mae
Sulfanona-mae
Sulfon-Mere
Sulfon-mere
Sulfona
Sulfona-MAE
Sulfona-Mae
Sulfone Ucb
Sulfone ucb
Sulfone, 4,4'-Diaminophenyl
Sulfonyldianiline
Sulphadione
Sulphon-Mere
Sulphon-mere
Sulphonyldianiline
Sumicure S
TL8005401
Tarimyl
UNII-8W5C518302
Udolac
W R 448
WLN: ZR DSWR DZ
WR 448
ZINC00006310
dapsone
p, p'-Sulfonyldianiline
p,p'-Diaminodiphenyl sulfone
p,p'-sulfonyldianiline
p,p-Diaminodiphenyl sulphone
p,p-Sulfonylbisbenzamine
p,p-Sulfonylbisbenzenamine
p,p-Sulphonylbisbenzamine
p,p-Sulphonylbisbenzenamine
p,p-Sulphonyldianiline
p-Aminophenyl sulfone
14
Ergocalciferolapproved, nutraceuticalPhase 492350-14-65280793
Synonyms:
'Ergosterol irradiated'
(+)-Vitamin D2
(3-beta,5Z,7E,22E)-9,10-Secoergosta-5,7,10,(19),22-tetraen-3-ol
(3S,5Z,7E,14xi,17alpha,22E)-9,10-secoergosta-5,7,10,22-tetraen-3-ol
(3S,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(3S,5Z,7E,22E)-9,10-secoergosta-5,7,10,22-tetraen-3-ol
(3beta,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(3beta,5Z,7e,22e)-9,10-Secoergosta-5,7,10(19),22-tetraen-3-ol
(5E,7E,22E)-9,10-Secoergosta-5,7,10,22-tetraen-3-ol
(5Z,7E,22E)-(3S)-9,10-seco-5,7,10(19),22-ergostatetraen-3-ol
(5Z,7E,22E)-(3S)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(5Z,7e,22e)-(3S)-9,10-Seco-5,7,10(19),22-ergostatetraen-3-ol
(5Z,7e,22e)-(3S)-9,10-Secoergosta-5,7,10(19),22-tetraen-3-ol
22-Tetraen 3beta 9,10,Secoergosta-5,7,10(19)-ol
31316-19-5
4-Methylene-3-[2-[tetrahydro-7a-methyl-1-(1,4,5-trimethyl-2-hexenyl)-4(3aH)-indanylidene]ethylidene]-Cyclohexanol
47768_SUPELCO
50-14-6
7489-18-1
7E677DC1-E1C4-4FC5-8F4A-BCE1857F7E87
8017-28-5
9,10,Secoergosta-5,7,10(19),22-tetraen 3.beta.-ol
9,10-Seco(5Z,7E,22E)-5,7,10(19),22-ergostatetraen-3-ol
9,10-Secoergosta-5,7,10(19),22-tetraen-3-beta-ol
9,10-Secoergosta-5,7,10(19),22-tetraen-3b-ol
95220_FLUKA
95220_SIGMA
AC-1355
AC1L1FIE
AC1NQXLH
AC1NS4DE
AC1NS9GI
AC1NSSVD
AC1NWAM3
AC1O5EDK
AC1O6WAM
ACon1_002187
Activated ergosterol
BPBio1_000418
BSPBio_000380
BSPBio_001974
Buco-D
C05441
C28H44O
CALCIFEROL IN A GELATIN MATRIX
CALCIFEROL, U.S.P.
CHEBI:28934
CHEMBL1536
CID11003810
CID3249
CID5280793
CID5315257
CID5353610
CID5356615
CID5702050
CID6432478
CID6536972
Calciferol
Calciferol (TN)
Calciferol (vitamin D2)
Calciferolum
Calciferon 2
Condacaps
Condocaps
Condol
Crtron
Crystallina
D-Arthin
D-Tracetten
D00187
DB00153
Daral
Davitamon D
Davitin
De-rat concentrate
Decaps
Dee-Osterol
Dee-Ron
Dee-Ronal
Dee-Roual
Deltalin
Deratol
Detalup
Diactol
Divit urto
Doral
Drisdol
Drisdol (TN)
E5750_SIGMA
EINECS 200-014-9
Ercalciol
Ergocalciferol
Ergocalciferol (D2)
Ergocalciferol (JP15/USP)
Ergocalciferol [INN:BAN:JAN]
Ergocalciferol oil
Ergocalciferol: Vitamin D
 
Ergocalciferolo
Ergocalciferolo [DCIT]
Ergocalciferols
Ergocalciferolum
Ergocalciferolum [INN-Latin]
Ergorone
Ergosterol activated
Ergosterol irradiated
Ergosterol, irradiated
Ertron
Fortodyl
Geltabs
Geltabs Vitamin D
HMS1920K20
HMS2091B19
HMS502I07
HSDB 819
Haliver
Hi-Deratol
Hyperkil
I05-0022
IDI1_000805
Infron
Irradiated ergosta-5,7,22-trien-3-beta-ol
Irradiated ergosta-5,7,22-trien-3.beta.-ol
Irradiated ergosta-5,7,22-trien-3beta-ol
Irradiated ergosterol
LMST03010001
LMST03010014
LS-3228
MEGxm0_000466
MLS001332467
MLS001332468
Metadee
Mina D2
MolPort-001-740-057
MolPort-001-793-930
MolPort-002-526-645
MolPort-003-666-178
MolPort-006-822-629
Mulsiferol
Mykostin
NCGC00142497-01
NCGC00179579-01
NCGC00179579-02
NSC 62792
NSC62792
Novovitamin-D
Oleovitamin D
Oleovitamin D, Synthetic
Oleovitamin D2
Osteil
Ostelin
Prestwick3_000420
Prestwick_554
Radiostol
Radstein
Radsterin
Rodine C
Rodinec
SMR000857106
SPECTRUM1500276
ST057150
STOCK1N-53397
Shock-ferol
Shock-ferol sterogyl
Sorex C.R
Sorex C.R.
Spectrum5_000666
Sterogyl
Synthetic Vitamin D
UNII-VS041H42XC
Uvesterol D
Uvesterol-D
VITAMIN D2
VITAMIN D2 WATER DISPERSABLE U.S.P.
VITAMIN_D2
Vigantol
Vio D
Vio-D
Viostdrol
Viosterol
Viosterol in Oil
Vitamin D
Vitamin D2
Vitamin- D2
Vitamin-?D2
Vitamina D2
Vitavel-D
WLN: L56 FYTJ A1 BY1&1U1Y1&Y1&1 FU2U- BL6YYTJ AU1 DQ
ZINC04474571
ZINC04629876
beta-Ol
bmse000510
component of Geltabs Vitamin D
delta-Arthin
delta-Tracetten
ergocalciferol
vitamin d-2
15
Folic Acidapproved, nutraceuticalPhase 4, Phase 3, Phase 2292459-30-36037
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
AI3-26387
AKOS000503224
ARONIS014410
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
Antianemia factor
Apo-Folic
BIDD:ER0563
BIDD:GT0641
BIF0608
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
FOL
Facid
Factor U
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
Folic Acid
Folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
Folina (Italy)
Folipac
 
Folsaeure
Folsan
Folsaure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
Incafolic
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
LS-2157
Liver Lactobacillus casei factor
MLS001304016
MLS001335861
Millafol
Mission prenatal
Mittafol
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-Pteroyl-L-glutamic acid
N-[(4-{[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
NINDS_000494
NSC 3073
Nifolin
Nifolin [Denmark]
Novofolacid
Novofolacid [Canada]
PGA
PGA (VAN)
Prestwick3_000627
Prestwick_230
PteGlu
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylglutamate
Pteroylglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
SMP2_000137
SMR000471860
SPBio_001357
SPECTRUM1502020
Serum Folate Level
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
Spectrum_001381
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin B9
Vitamin Bc
Vitamin Be
Vitamin M
bmse000299
folic acid
nchembio.108-comp10
16Analgesics, Non-NarcoticPhase 4, Phase 3, Phase 2, Phase 1, Phase 05184
17Anti-Inflammatory AgentsPhase 4, Phase 2, Phase 3, Phase 1, Phase 08478
18Anti-Inflammatory Agents, Non-SteroidalPhase 4, Phase 3, Phase 2, Phase 1, Phase 03549
19AnalgesicsPhase 4, Phase 3, Phase 2, Phase 1, Phase 09358
20Antirheumatic AgentsPhase 4, Phase 3, Phase 2, Phase 1, Phase 08496
21Complement C1 Inhibitor ProteinPhase 4, Phase 3, Phase 2, Phase 142
22AntibodiesPhase 4, Phase 3, Phase 2, Phase 14477
23Anti-Allergic AgentsPhase 4, Phase 2, Phase 3, Phase 11312
24Complement C1 Inactivator ProteinsPhase 4, Phase 3, Phase 2, Phase 139
25
BradykininPhase 4, Phase 3, Phase 2, Phase 1, Phase 04758-82-2439201
Synonyms:
Callidin I
Kallidin 9
 
Kallidin I
L-Arginyl-L-prolyl-L-prolylglycyl-L-phenylalanyl-L-seryl-L-prolyl-L-phenylalanyl-L-Arginine
L-Bradykinin
26ImmunoglobulinsPhase 4, Phase 3, Phase 2, Phase 14477
27VitaminsPhase 43857
28Trace ElementsPhase 43900
29Immunosuppressive AgentsPhase 4, Phase 3, Phase 2, Phase 1, Phase 010422
30KininogensPhase 4, Phase 3, Phase 2, Phase 1, Phase 047
31Bone Density Conservation AgentsPhase 4, Phase 22600
32ErgocalciferolsPhase 4923
33vitamin dPhase 41524
34Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 2, Phase 1, Phase 018510
35Bradykinin B2 Receptor AntagonistsPhase 4, Phase 3, Phase 2, Phase 1, Phase 013
36Bradykinin Receptor AntagonistsPhase 4, Phase 3, Phase 2, Phase 1, Phase 017
37Complement Inactivating AgentsPhase 4, Phase 3, Phase 2, Phase 1, Phase 071
38Complement System ProteinsPhase 4, Phase 3, Phase 2, Phase 1, Phase 0190
39MicronutrientsPhase 43901
40Complement C1sPhase 4, Phase 3, Phase 2, Phase 130
41Cholinergic AgentsPhase 4, Phase 3, Phase 23243
42Neurotransmitter AgentsPhase 4, Phase 2, Phase 3, Phase 1, Phase 014795
43Cholinergic AntagonistsPhase 4, Phase 3, Phase 21423
44EbastinePhase 4490729-43-4
45Respiratory System AgentsPhase 4, Phase 2, Phase 3, Phase 13931
46Anti-Asthmatic AgentsPhase 4, Phase 2, Phase 3, Phase 12796
47LevocetirizinePhase 4, Phase 3, Phase 261
48Bronchodilator AgentsPhase 4, Phase 3, Phase 2, Phase 12377
49Dermatologic AgentsPhase 4, Phase 3, Phase 24555
50AntipruriticsPhase 4, Phase 3, Phase 2619

Interventional clinical trials:

(show top 50)    (show all 278)
idNameStatusNCT IDPhase
1Levocetirizine Plus Bed-Time Hydroxyzine in the Management of Corticodependent Chronic Urticaria Versus Levocetirizine Alone in High DosesCompletedNCT01250652Phase 4
2Evaluation of the Inhibitory Effect of 5 Anti-Histamines in UrticariaCompletedNCT01940393Phase 4
3Omalizumab in Chronic Spontaneous Urticaria Patients Non Responding to Initial Standard antihistaminE TreatmentCompletedNCT02550106Phase 4
4A Study to Assess and Compare the Effects of 5 mg vs. 20 mg Desloratadine on the Development of Cold Urticaria LesionsCompletedNCT00600847Phase 4
5CUTE (Chronic Urticaria Treatment Evaluation)CompletedNCT00264303Phase 4
6Desloratadine 5, 10 and 20mg in Patients With Cold UrticariaCompletedNCT01444196Phase 4
7Study for the Treatment of Chronic Idiopathic Urticaria With High Doses of AERIUS (Desloratadine) (Study P04849)CompletedNCT00536380Phase 4
8A Comparison of Aerius Continuous Treatment Versus Aerius PRN for Chronic Idiopathic Urticaria (Study P03147)CompletedNCT00783354Phase 4
9An Open-Label Study of the Effects of Desloratadine (Aerius.) Treatment on the Quality of Life of Patients With Chronic Idiopathic Urticaria (Study P02540)CompletedNCT00795522Phase 4
10A Comparative Double-Blind, Double- Dummy Study of Desloratadine (DL) 5 MG Once Daily, Cetirizine 10 MG Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (Study P03735)CompletedNCT00751218Phase 4
11Effects of Bilastine on F1 Simulator Driving Performance in Patients Affected by Allergic Rhinitis and/or UrticariaCompletedNCT02576041Phase 4
12Postoperative Antibiotic Requirements Following Immediate Breast ReconstructionCompletedNCT01244698Phase 4
13A Post Marking Study to Evaluate the Safety of FluMist in ChildrenCompletedNCT00569894Phase 4
14Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix TM) Administered in Healthy AdolescentsCompletedNCT00534638Phase 4
15Evaluation of Praziquantel Dosage for Treatment of Schistosomiasis in BrazilCompletedNCT00403611Phase 4
16Clevidipine for Vasoreactivity Evaluation of the Pulmonary Arterial BedCompletedNCT01121458Phase 4
17Safety of Astepro 0.15% Nasal Spray and Astepro 0.1% Nasal Spray in Children Ages >6 Months to <6 Years With ARCompletedNCT01880840Phase 4
18Postmarketing Immunogenicity Study in HAE Subjects Treated With BerinertCompletedNCT01467947Phase 4
19Efficacy, Safety and Tolerability of a Self-Administered Subcutaneous Formulation of Icatibant for the Treatment of Acute Attacks of Hereditary AngioedemaCompletedNCT01457430Phase 4
20A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZECompletedNCT00914966Phase 4
21Sustained Effect of Urticaria Remission With Relatively High Dose Vitamin D Supplementation After Omalizumab DiscontinuationRecruitingNCT02742805Phase 4
22The Efficacy and Safety of Desloratadine With Levocetirizine in Treatment of Chronic Idiopathic UrticariaRecruitingNCT00346606Phase 4
23A Study to Assess the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria (CIU)RecruitingNCT02392624Phase 4
24Clinical Utility Of Genetic Screening For HLA-B*1301, On Susceptibility To Dapsone Hypersensitivity SyndromeRecruitingNCT02550080Phase 4
25Effect of Omalizumab (Xolair) on Basophils in Patients With Chronic Idiopathic UrticariaActive, not recruitingNCT01701583Phase 4
26A Call Center During HAE Attacks (SOS HAE)Active, not recruitingNCT01679912Phase 4
27A Comparative Double-blind, Double-dummy Study of Desloratadine (DL) 5 mg Once Daily, Cetirizine 10 mg Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (Study P03736)TerminatedNCT00751166Phase 4
28C1-INH Compared to Placebo at the Time of Prodromal Symptoms for Hereditary Angioedema (HAE) ExacerbationWithdrawnNCT01151735Phase 4
29Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria PatientsCompletedNCT01803763Phase 2, Phase 3
30Glucocorticoids With Antihistamines Versus Antihistamines in Acute Urticaria in EmergencyCompletedNCT02565680Phase 2, Phase 3
31Effects of 5 mg vs. 20 mg Desloratadine on Skin Lesions in Patients With Chronic Urticaria (CU)CompletedNCT00598611Phase 3
32Efficacy Study for the Symptomatic Treatment of Chronic Idiopathic UrticariaCompletedNCT00421109Phase 3
33An Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Chronic Urticaria (MK-4117-201)CompletedNCT01916967Phase 3
34A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor AntagonistsCompletedNCT01264939Phase 3
35How Desloratadine (Clarinex, Aerius) Affects Quality of Life in Patients With Chronic Idiopathic Urticaria (Have Had Hives for 6 Weeks or Longer)(Study P02988)CompletedNCT00795158Phase 3
36Bilastine Updosing - Characterization of Underlying MechanismsCompletedNCT01271075Phase 2, Phase 3
37A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) TreatmentCompletedNCT01287117Phase 3
38A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)CompletedNCT01292473Phase 3
39Study to Compare the Efficacy and Safety Between Levocetirizine and Loratadine for Chronic Idiopathic UrticariaCompletedNCT00525382Phase 3
40Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 1 to Less Than 6 Years Suffering From Allergic Rhinitis or Chronic Urticaria of Unknown OriginCompletedNCT00619801Phase 3
41Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to TherapyCompletedNCT01723072Phase 3
42Multicenter Pilot Phase III Clinical Trials of JDP-205 iv Injection for the Treatment of Acute Urticaria Associated With an Acute Allergic Reaction.CompletedNCT02023164Phase 3
43Safety of Desloratadine in Children With Allergy Sensitivity and Chronic Hives, Who Are Poor Metabolizers of Desloratadine (Study P02994)CompletedNCT00757562Phase 3
44Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 MonthsCompletedNCT00628108Phase 3
45A Trial of Point of Care Information in Ambulatory PediatricsCompletedNCT00368823Phase 3
46Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)CompletedNCT00288704Phase 3
47The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in CanadaCompletedNCT01105507Phase 3
48The Effect of Xolair ® (Omalizumab) in Mastocytosis PatientsCompletedNCT01333293Phase 2, Phase 3
49A 6 Month Safety and Efficacy Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) in the Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and OlderCompletedNCT00953147Phase 3
50A 6 Month Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and OlderCompletedNCT01067105Phase 3

Search NIH Clinical Center for Urticaria

Inferred drug relations via UMLS65/NDF-RT43:

Genetic Tests for Urticaria

About this section

Anatomical Context for Urticaria

About this section

MalaCards organs/tissues related to Urticaria:

33
Skin, Testes, Liver, Breast, T cells, Endothelial, Lung

FMA organs/tissues related to Urticaria:

16
The upper dermis

Animal Models for Urticaria or affiliated genes

About this section

MGI Mouse Phenotypes related to Urticaria:

38
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053818.5F2, HRH2, IL10, IL13, NLRP3, PTGS1
2MP:00107718.1CD40LG, F2, IL10, IL13, IL1RN, NLRP3
3MP:00053907.8CD40LG, F2, IL10, IL13, IL1RN, NLRP3
4MP:00053766.7CD40LG, CD79A, F2, FCER1A, HRH1, HRH2
5MP:00053975.8CCL11, CD40LG, CD79A, CMA1, F2, FCER1A
6MP:00053875.8CCL11, CD40LG, CD79A, CMA1, CPN1, F2

Publications for Urticaria

About this section

Articles related to Urticaria:

(show top 50)    (show all 1558)
idTitleAuthorsYear
1
Myoclonic status and central fever in Angelman syndrome due to paternal uniparental disomy. (26559560)
2015
2
Comparison of effects of pioglitazone and glimepiride on plasma soluble RAGE and RAGE expression in peripheral mononuclear cells in type 2 diabetes: randomized controlled trial (PioRAGE). (24727234)
2014
3
Characterization of functional domains of the cblD (MMADHC) gene product. (24722857)
2014
4
The annexin 5 in serums of pregnant women and patients with particular types of cancer]. (25080795)
2014
5
Anticancer effects of deproteinized asparagus polysaccharide on hepatocellular carcinoma in vitro and in vivo. (24310501)
2013
6
A zebrafish model of intrahepatic cholangiocarcinoma by dual expression of hepatitis B virus X and hepatitis C virus core protein in liver. (22729936)
2012
7
Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry. (22898389)
2012
8
Silent mutation in long QT syndrome: pathogenicity prediction by computer simulation. (22001705)
2012
9
Impact of a bronchiolitis clinical care pathway on treatment and hospital stay. (22193364)
2012
10
Lichen planus of the larynx. (21272411)
2011
11
Mucoepidermoid carcinoma as a masquerade syndrome of scleral melting and granulomatous kerato-uveitis. (21484645)
2011
12
Ectopic pregnancy: using the hCG ratio to select women for expectant or medical management. (21306315)
2011
13
Bladder augmentation versus urinary diversion in patients with spina bifida in the United States. (21575969)
2011
14
Intraoperative assessment of surgical margins during breast conserving surgery of ductal carcinoma in situ by use of radiofrequency spectroscopy. (21885281)
2011
15
PHOX2B immunolocalization of the candidate human retrotrapezoid nucleus. (19888871)
2010
16
Atomic force microscopy reveals binding of mRNA to microtubules mediated by two major mRNP proteins YB-1 and PABP. (18652827)
2008
17
Combined high-resolution array-based comparative genomic hybridization and expression profiling of ETV6/RUNX1-positive acute lymphoblastic leukemias reveal a high incidence of cryptic Xq duplications and identify several putative target genes within the commonly gained region. (17690704)
2007
18
Tailor treatment to the patient in thyrotoxicosis. (17784663)
2007
19
Intravenous administration of activated protein C in Pseudomonas-induced lung injury: impact on lung fluid balance and the inflammatory response. (16553944)
2006
20
Using Drosophila to decipher how mutations associated with human branchio-oto-renal syndrome and optical defects compromise the protein tyrosine phosphatase and transcriptional functions of eyes absent. (15802522)
2005
21
Procalcitonin as a marker of bacterial infection in the emergency department: an observational study. (14975050)
2004
22
Valproate, bipolar disorder and polycystic ovarian syndrome. (12656935)
2003
23
Substance P induces tumor necrosis factor-alpha release from human skin via mitogen-activated protein kinase. (10854844)
2000
24
Human Herpesvirus 8 and Protection from AIDS Dementia Complex. (11867000)
2000
25
Immunoadhesins of interleukin-6 and the IL-6/soluble IL-6R fusion protein hyper-IL-6. (10089096)
1999
26
Inhibition of microtubule assembly by HPC-1/syntaxin 1A, an exocytosis relating protein. (15216893)
1999
27
Effect of Anapsos (Polypodium leucotomos extract) on in vitro production of cytokines. (9056057)
1997
28
Targeted overexpression of parathyroid hormone-related peptide in chondrocytes causes chondrodysplasia and delayed endochondral bone formation. (8816783)
1996
29
Staphylococcus aureus nasal carriage in rheumatoid arthritis: antibody response to toxic shock syndrome toxin-1. (8976639)
1996
30
Paradoxical cerebral embolism originating from thrombus in tumour veins as presenting manifestation of retroperitoneal liposarcoma. (8461249)
1993
31
Characterization of adenosine deaminase (ADA)-negative B-lymphoblastoid cells cocultured with ADA-positive fibroblasts. (8500601)
1993
32
Heterologous epidermal growth factor receptor (EGF-R) expression in larynx cancer cell lines: evidence for the existence of structurally modified receptors. (8291440)
1993
33
Induction of arousal in hibernating European hamsters (Cricetus cricetus L.) by vasopressin infusion in the lateral septum. (8131059)
1993
34
Oculoglandular syndrome. Cat-scratch disease without the cat scratch. (1561160)
1992
35
The zinc finger protein GLI transforms primary cells in cooperation with adenovirus E1A. (1825351)
1991
36
Bronchial symptoms and respiratory function in the natural gas extraction industry. The role of Pi phenotype and chemical pollution]. (2034859)
1991
37
Characterization of the antigen identified by Po66. A monoclonal antibody raised against a lung squamous cell carcinoma. (2541906)
1989
38
Disk diffusion testing of susceptibility of Mycobacterium fortuitum and Mycobacterium chelonei to antibacterial agents. (526002)
1979
39
Arthrographic findings in Legg-CalvAc-Perthes disease and transient synovitis of the hip. (670266)
1978
40
The effect of pan-retinal photo-coagulation on rubeosis iridis. (945697)
1976
41
Repair of aortic arch interruption in the neonate. (4910631)
1970
42
A case report of pituitary tumor presenting as Forbes-Albright syndrome: determination of pituitary prolactin content. (4168414)
1967
43
Early Tahitian views on elephantiasis. (13443422)
1957
44
45
46
47
48
49
50

Variations for Urticaria

About this section

Expression for genes affiliated with Urticaria

About this section
Search GEO for disease gene expression data for Urticaria.

Pathways for genes affiliated with Urticaria

About this section

Pathways related to Urticaria according to GeneCards Suite gene sharing:

(show all 19)
idSuper pathwaysScoreTop Affiliating Genes
19.5F2, PLCG2, PTGS1
29.5CD40LG, IL10, TNF
39.4CD40LG, CXCL8, PLCG2, TNF
49.4CCL11, CD40LG, IL10
59.4IL10, IL13, TNF
69.4IL10, IL13, TNF
7
Show member pathways
9.3CD40LG, CXCL8, IL3, TNF
89.3CCL11, IL10, IL13
99.1CD40LG, CXCL8, IL10, TNF
10
Show member pathways
9.0CD40LG, CXCL8, IL10, TNF
119.0CD79A, FCER1A, IL10, IL3, TNF
12
Show member pathways
9.0CD79A, FCER1A, IL13, IL3, PLCG2, TNF
138.7C1S, CXCL8, IL10, NLRP3, TNF
14
Show member pathways
8.7CXCL8, IL10, IL13, IL3, TNF
158.6CXCL8, IL10, IL13, IL1RN, NLRP3, TNF
16
Show member pathways
8.3CCL11, CD40LG, FCER1A, IL10, IL13, IL3
17
Show member pathways
7.9CCL11, CD40LG, CXCL8, IL10, IL13, IL3
18
Show member pathways
7.7CCL11, CD40LG, CXCL8, FCER1A, IL10, IL13
19
Show member pathways
7.2CCL11, CD40LG, CXCL8, F2, FCER1A, IL10

GO Terms for genes affiliated with Urticaria

About this section

Biological processes related to Urticaria according to GeneCards Suite gene sharing:

(show all 9)
idNameGO IDScoreTop Affiliating Genes
1regulation of immunoglobulin secretionGO:005102310.6CD40LG, TNF
2positive regulation of mast cell degranulationGO:004330610.6FCER1A, IL13
3positive regulation of release of sequestered calcium ion into cytosolGO:005128110.4F2, IL13
4receptor biosynthetic processGO:003280010.4IL10, TNF
5negative regulation of cytokine secretion involved in immune responseGO:000274010.3IL10, TNF
6response to inactivityGO:001485410.2F2, IL10
7signal transductionGO:00071658.8CCL11, CXCL8, FCER1A, IL13, NLRP3, PLCG2
8inflammatory responseGO:00069548.2CCL11, HRH1, IL10, NLRP3, PTGS1, TNF
9immune responseGO:00069557.8CCL11, CMA1, CXCL8, IL10, IL13, IL3

Molecular functions related to Urticaria according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1histamine receptor activityGO:00049699.7HRH1, HRH2

Sources for Urticaria

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet